XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure Using PASylation® Technology
Brian Johnson, Antlia Bioscience’s CEO commented, "chronic heart failure is a significantly unaddressed medical condition and a major public health concern. XL-protein's PASylation® technology will allow us to safely and effectively translate our peptide into a meaningful therapeutic option for patients with chronic heart failure.